Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.
3.

[Avastin-Lucentis: off-label and surroundings].

Messori A.

Recenti Prog Med. 2014 Apr;105(4):137-40. doi: 10.1701/1459.16117. Italian.

PMID:
24770536
4.
5.
6.

Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Ziemssen F, Grisanti S, Bartz-Schmidt KU, Spitzer MS.

Drugs Aging. 2009;26(4):295-320. doi: 10.2165/00002512-200926040-00002. Review.

PMID:
19476398
7.

Minister rules out use of Avastin over Lucentis for wet AMD.

Kmietowicz Z.

BMJ. 2015 Apr 16;350:h2050. doi: 10.1136/bmj.h2050. No abstract available.

PMID:
25882175
8.

Avastin and Lucentis: a guide through the legal maze.

Lock D.

BMJ. 2015 Apr 1;350:h1377. doi: 10.1136/bmj.h1377. No abstract available.

PMID:
25834023
9.

[Lucentis versus Avastin--is there a light at the end of the tunnel for age-related macular degeneration patients?].

Waisbourd M, Leibovitch I, Loewenstein A, Yassur Y.

Harefuah. 2008 Jul;147(7):605-6, 662. Hebrew.

PMID:
18814519
10.

Bevacizumab (AVASTIN) and age-related macular degeneration. Lower cost does not justify taking risks.

[No authors listed]

Prescrire Int. 2015 Sep;24(163):201-4. Review.

PMID:
26417625
11.

Why using Avastin for eye disease is so difficult.

Torjesen I.

BMJ. 2012 May 1;344:e3012. doi: 10.1136/bmj.e3012. No abstract available.

PMID:
22549057
12.

Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.

Hawkes N.

BMJ. 2012 May 9;344:e3275. doi: 10.1136/bmj.e3275. No abstract available.

PMID:
22573655
13.

Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review.

Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M.

Curr Opin Ophthalmol. 2010 May;21(3):218-26. doi: 10.1097/ICU.0b013e3283386783. Review.

PMID:
20393293
14.

[Results of an expert survey on VEGF inhibitors in ophthalmology].

Kühn T.

Klin Monbl Augenheilkd. 2011 Jul;228(7):607-12. doi: 10.1055/s-0029-1245827. Epub 2011 Apr 6. German.

PMID:
21472638
15.

Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds.

Torjesen I.

BMJ. 2013 Jul 23;347:f4678. doi: 10.1136/bmj.f4678. No abstract available.

PMID:
23881948
16.

Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness.

Raftery J, Clegg A, Jones J, Tan SC, Lotery A.

Br J Ophthalmol. 2007 Sep;91(9):1244-6. Epub 2007 Apr 12.

17.

Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review.

Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, Antes G, Lelgemann M.

Br J Ophthalmol. 2011 Mar;95(3):308-17. doi: 10.1136/bjo.2009.178574. Epub 2010 Oct 22. Review.

PMID:
20971791
18.

Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.

Landa G, Amde W, Doshi V, Ali A, McGevna L, Gentile RC, Muldoon TO, Walsh JB, Rosen RB.

Ophthalmologica. 2009;223(6):370-5. doi: 10.1159/000227783. Epub 2009 Jul 8.

PMID:
19590252
19.

Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and intravitreal biologics for ocular inflammation.

Yeh S, Albini TA, Moshfeghi AA, Nussenblatt RB.

Am J Ophthalmol. 2012 Sep;154(3):429-435.e2. doi: 10.1016/j.ajo.2012.05.011. Review.

20.

Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.

Schmucker C, Antes G, Lelgemann M.

Surv Ophthalmol. 2009 Nov-Dec;54(6):705-7. doi: 10.1016/j.survophthal.2009.08.002. Review. No abstract available.

PMID:
19818262

Supplemental Content

Support Center